Overview

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
To determine the feasibility and safety of administering YM155 in combination with docetaxel
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Docetaxel
Hormones
Prednisone